Drugs / NA17.A2
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01723813 | Apr 2012 → Apr 2015 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT01191034 | Aug 2010 → Aug 2012 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT00145158 | Jan 2005 → Nov 2007 | melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01307618 | Feb 2011 → Jan 2015 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NA17.A2 | “These peptides are the following: MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2 (ALKD), and NA17.A2 (20% intradermally and 80% subcutaneously); NY-ESO-1.A2 and...” NCT00145158 ↗ |
| Modality | Peptide | “The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor.” NCT01191034 ↗ |
| Route | Subcutaneous | “NA17.A2 (20% intradermally and 80% subcutaneously)” NCT00145158 ↗ |